Remedent (OTCMKTS:REMI) is a Canadian-based oral health diagnostics and therapeutics company focused on the development, commercialization and licensing of biomarker-based technologies for the early detection and management of oral diseases. The company’s proprietary platform integrates molecular biology, immunoassay and advanced analytics to deliver non-invasive screening tests designed for use in dental practices, medical clinics and pathology laboratories. Headquartered in Vancouver, British Columbia, Remedent serves both the domestic Canadian market and select international partners across North America and Europe.
At the core of Remedent’s offering is a suite of salivary diagnostics aimed at identifying biomarkers linked to oral cancer, periodontal disease and systemic conditions that manifest in the oral cavity. These assays employ patented antibody-based detection methods to quantify risk profiles for patients, enabling dentists and physicians to intervene earlier in the disease process. In addition to its diagnostic tests, the company has a pipeline of follow-on products that includes point-of-care screening kits and remote monitoring tools intended to support telehealth initiatives and enhance patient engagement.
Remedent maintains strategic collaborations with leading research institutions and clinical laboratories to validate its technologies and accelerate regulatory approvals. Through agreements with university spin-offs and global distributors, the company has gained market access in key territories including the United States, Germany and Japan. Its business model encompasses direct sales to professional end users as well as licensing arrangements that provide recurring revenues and broad distribution reach.
Founded in 2002, Remedent has steadily expanded its intellectual property portfolio and operational footprint under the leadership of CEO Dr. Emily Ross, a molecular biologist with over 20 years of experience in diagnostics development. The company’s board includes seasoned executives from the dental, biotech and regulatory fields, positioning Remedent to navigate complex commercialization pathways. Looking ahead, Remedent is focused on growing adoption of its flagship tests and advancing next-generation assays for emerging oral health challenges.
